Is Prolotherapy a Hoax? An Honest Read of the Evidence

Written by Robert Stall, MD

Updated September 2026 ·9 min read

The question is asked often enough that it deserves a direct answer rather than a defensive one. The short version: prolotherapy is not a hoax, but a good deal of what is claimed for it is unsupported, and the gap between the two is where the scepticism comes from.

What follows is the evidence as taught by Robert Stall, MD — board certified in physical medicine and rehabilitation, subspecialty board certified in pain medicine, and a clinician who teaches the technique while declining to oversell it.

Why the scepticism is reasonable

Four things about this field genuinely invite doubt, and pretending otherwise helps nobody.

It is usually paid out of pocket. Treatments that insurers decline to cover attract suspicion, fairly or not.

The claims are frequently enormous. Clinics advertise regeneration, cure and surgery avoidance for conditions where the trial evidence supports none of those words.

The studies contradict each other. They genuinely do — and there is a specific reason, covered below, that is more interesting than either side usually admits.

It gets sold alongside things that do not work. Proximity to stem cell clinics operating outside current FDA rules has cost the whole category credibility.

There is a defined mechanism, and it is not mysterious

Prolotherapy works by provoking a healing response in tissue that has stopped healing on its own. The sequence is specific and observable.

Injection of hyperosmolar dextrose creates deliberate inflammation in pathological tissue along with some local bleeding. That triggers cytokine cascades and chemotaxis of inflammatory cells, raising cellular activity and growth factor concentration in the area. Stall dates this first stage at three to seven days.

The proliferation stage begins around 72 hours and runs up to six weeks, with myofibroblasts, fibroblasts and endothelial cells laying down new type I and type III collagen.

Remodelling then continues for up to two years, during which collagen cross-links mature and the fibrillar pattern of healthy tendon and ligament re-establishes, replacing what Stall calls “the disorganised, fragile structure of prior tendinosis.”

That is a coherent biological account. It is the same sequence that follows PRP, because — as Stall teaches — “PRP is a subcategory of prolotherapy.”

Why the studies disagree: the part both camps skip

Here is the finding that explains the contradictory literature better than any argument about bias.

Platelet concentrations from above baseline up to about 750,000 per microlitre are supported as effective for tissue regeneration by several trials. Above that, Stall states, “there was no evidence that platelet concentrations greater than 750,000 necessarily provided any better tissue regeneration in soft tissue injury.”

And at very high concentrations the effect on bone regeneration was inhibitory — those subjects “did worse than controls who had no PRP treatment at all.”

Now consider what that does to a body of literature. Trials using preparations in the effective range report benefit. Trials using very concentrated preparations may report no benefit or harm. Both publish under the heading “PRP”. A meta-analysis pooling them produces a washed-out average that describes neither.

Compounding it, multiple classification systems exist and, in Stall's words, “none of these classification systems have been universally accepted as a universal standard, giving rise in part to the confusion.” Two studies labelled identically may differ in leukocyte content and by fourfold in platelet concentration.

So the contradictory evidence is not proof the treatment fails. It is substantially a measurement problem — though that is an explanation, not a defence, and it cuts both ways.

What the evidence does support

Specific indications with published results, stated at the strength the studies actually justify:

• Lateral epicondylitis (tennis elbow) — a single PRP injection produced significantly greater improvement than corticosteroid in one study, with benefit maintained at two years.
• Achilles tendon repair — surgical repair augmented with PRP showed significant improvement in recovered range of motion and return to sport compared with repair alone.
• Lumbar interbody fusion — aids bone healing and decreases the rate of pseudoarthrosis.
• Adhesive capsulitis — corticosteroid better in the short term, PRP better in the long term for pain and disability.

Notice the shape of that list: mostly tendon and ligament, mostly with defined pathology, and one result maintained at two years. That is a narrower claim than most clinic websites make, and it is the claim that holds.

What is not supported

Being specific here is what makes the rest credible.

• “More platelets means better results.” Contradicted above 750,000 per microlitre, and reversed for bone.
• Alpha-2-macroglobulin as a premium upgrade. In a prospective trial of 75 knee osteoarthritis patients at NYU Langone, A2M had similar efficacy to corticosteroid and was “no better than regular PRP” at six and twelve weeks.
• A fixed series of three. The ideal regimen “remains undefined and there are contradictions within the published literature.” The main study supporting three injections had an unexplained design quirk, a small sample, and has not been replicated.
• Adipose-derived stem cell products for cushioning and support. Not an evidence question — these are no longer permitted under current FDA guidance.
• Regeneration of a joint. Nothing in this category regrows cartilage in an arthritic knee.

So is it a hoax?

No — there is a defined mechanism, a described healing sequence, and published benefit in specific indications, particularly tendon.

But the honest framing is narrower than the marketing. It is a treatment with moderate evidence in selected soft-tissue conditions, where preparation varies enormously between clinics, where the optimal regimen is genuinely unknown, and where the effect is measured in months of remodelling rather than immediate relief.

A clinic that says that is being straight with you. A clinic promising regeneration, cure or guaranteed surgery avoidance is describing something the evidence does not contain.

Questions that separate the two

1. What platelet concentration does your system produce? A clinic that cannot answer has not characterised its own preparation.
2. Leukocyte-rich or leukocyte-poor, and why for my condition?
3. What does the evidence show for my specific diagnosis — not for regenerative medicine generally?
4. How many injections, and on what basis is that number chosen?
5. When do we decide this has not worked? A date, agreed in advance.
6. What are you not claiming? The most informative question you can ask.